Table Title	Table Subsect ion	Indication	Treatment	Rating Panelist 1	Rating Panelist 2	Rating Panelist 3	Rating Panelist 4	Rating Panelist 5	Rating Panelist 6	Rating Panelist 7	Rating Panelist 8	Rating Panelist 9	Rating Panelist 10	Rating Panelist 11	Rating Panelist 12	Rating Panelist 13	Rating Panelist 14	Rating Panelist 15	Rating Panelist 16	Rating Panelist 17	Median	AUC Rating
Table 1: Asymptom atic, High Gradient, Severe AS		1.• LVEF ≥50%• Vmax 4 to 4.9 m/sec• Negative exercise stress test• No predictors of rapid progression / symptom onset / adverse events (e.g., ∆Vmax >0.3 m/s/yr, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension)• High or intermediate surgical risk	No Intervention	7	4	7	7	7	5	7	9	6	6	7	7	4	8	7	7	7	7	Α
			AVR (TAVR or SAVR)	4	6	4	4	5	5	5	3	6	6	4	5	6	3	5	4	5	5	M

2. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• Negative exercise stress test• No predictors of rapid progression / symptom onset / adverse events (e.g., △Vmax >0.3 m/s/yr, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension)• Low surgical risk	No Intervention	7	4	8	7	7	5	7	8	6	6	7	6	6	7	7	7	7	7	А
	AVR (TAVR or SAVR)	5	6	6	5	5	5	5	3	6	7	4	6	6	4	5	4	7	5	M
3. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• High risk profession (e.g. airline pilot) or lifestyle (e.g. competitive athlete) or anticipated prolonged time away from close medical supervision• Low surgical risk	No Intervention	6	1	4	7	5	4	4	7	5	5	3	6	3	4	3	5	4	4	M
	AVR (TAVR or SAVR)	5	9	8	6	7	7	7	4	7	7	8	8	7	7	7	6	5	7	А

4. • LVEF Vmax 4 to m/sec• No exercise s test• One predictors progressic symptom adverse e (e.g., ΔVn m/s/yr, se valve calc elevated I excessive hypertrop absence o hypertens High or intermedic surgical ri	egative stress or more s of rapid on / onset / events nax >0.3 evere effication, BNP, or e LV hy in the of sion)• ate No Intervention	4	3	2	6	5	4	4	8	4	6	4	4	4	6	5	4	4	4	M
	AVR (TAVR or SAVR)	7	7	7	5	5	7	7	5	6	6	7	8	6	7	8	7	7	7	Α

5. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• Negative exercise stress test• One or more predictors of rapid progression / symptom onset / adverse events(e.g., ΔVmax >0.3 m/s/yr, severe valve calcification, elevated BNP, or excessive LV hypertrophy in the absence of hypertension)• Low surgical risk	No Intervention	3	3	4	5	5	4	4	7	4	2	4	4	4	4	5	3	3	4	M
	AVR (TAVR or SAVR)	8	7	6	6	6	7	8	5	7	8	8	8	6	8	8	8	8	8	А
6. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• Abnormal exercise stress test• High or intermediate surgical risk	No Intervention	1	1	2	6	2	3	3	3	3	2	3	3	2	3	2	3	3	3	R
	AVR (TAVR or SAVR)	9	9	8	7	8	8	8	8	8	9	8	8	8	8	8	8	7	8	Α
7. • LVEF ≥50%• Vmax 4 to 4.9 m/sec• Abnormal exercise stress test• Low surgical risk	No Intervention	1	1	4	5	4	3	2	1	2	2	2	3	4	2	3	2	2	2	R
	AVR (TAVR or SAVR)	9	9	7	8	7	8	8	8	8	9	8	8	8	8	8	8	7	8	А

8. • LVEF ≥50%• Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg)• High or intermediate surgical risk	No Intervention	5	1	2	6	2	2	4	5	4	1	4	6	2	4	3	4	1	4	M
	AVR (TAVR or SAVR)	6	9	8	7	8	8	7	7	7	9	7	7	8	7	8	7	9	7	Α
9. • LVEF ≥50%• Very severe AS (Vmax ≥5 m/sec or mean gradient ≥60 mmHg)• Low surgical risk	No Intervention	5	1	2	5	2	2	2	4	2	2	2	4	2	2	2	2	1	2	R
	AVR (TAVR or SAVR)	6	9	8	7	8	8	8	8	8	7	8	8	8	8	8	8	9	8	А
10.• LVEF <50%• Vmax ≥4 m/sec or mean gradient ≥40 mmHg• High or intermediate surgical risk	No Intervention	1	1	1	3	1	1	2	2	2	1	2	2	2	2	2	2	4	2	R
	AVR (TAVR or SAVR)	9	9	9	7	9	9	8	8	8	9	8	8	8	8	9	8	5	8	А
11. • LVEF <50%• Vmax ≥4 m/sec or mean gradient ≥40 mmHg• Low surgical risk	No Intervention	1	1	1	2	1	1	1	1	8	1	1	2	2	1	2	1	6	1	R
	AVR (TAVR or SAVR)	9	9	9	8	9	9	9	9	1	9	9	8	9	9	9	9	6	9	Α

	and sur aso	. •Undergoing other cardiac rgery or cending aortic rgery	No Intervention	1	3	2	1	1	2	1	1	1	1	1	1	1	1	2	1	1	1	R
			AVR (TAVR or SAVR)	0	6	8	0	9	4	9	9	0	9	9	9	9	9	9	9	9	9	Α
Table 2: Flow, Gradient, and Ejection Fraction	Ejectio n AV Fractio n res (<50%) LV Low gra res dos ect sev	sting echo• 'EF 20 to <50%• w flow• Low adient• Flow serve on low se dobutamine ho• Truly vere AS• High intermediate	No Intervention	1	2	1	5	1	1	2	2	2	2	2	4	1	2	2	2	2	2	R
			BAV (bridge to decision)	4	7	2	5	1	1	3	4	5	2	2	2	3	4	2	4	5	3	R
			AVR (TAVR or SAVR)	9	8	9	5	8	8	8	8	8	8	8	8	9	8	8	8	7	8	Α

14. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo• LVEF 20 to <50%• Low flow• Low gradient• Flow reserve on low dose dobutamine echo• Truly severe AS• Low surgical risk	No Intervention	1	2	8	4	1	8	1	1	1	2	1	4	2	1	2	1	1	1	R
	BAV (bridge to decision)	3	5	2	5	2	3	2	2	1	1	1	2	2	2	2	2	2	2	R
	AVR (TAVR or SAVR)	0	8	3	6	9	3	9	9	9	8	9	8	9	9	8	9	9	9	Α
15. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo• LVEF 20 to <50%• Low flow• Low gradient• Flow reserve on low dose dobutamine echo• Pseudo severe AS	No Intervention	9	4	8	8	8	8	8	8	8	8	8	7	8	8	7	8	5	8	А
	BAV (bridge to decision)	2	4	1	4	1	2	2	3	2	2	2	2	2	2	2	2	5	2	R
	AVR (TAVR or SAVR)	1	3	3	3	1	2	2	1	2	2	2	4	2	2	2	2	5	2	R

No Intervention	5	2	4	7	4	3	4	5	8	4	4	5	2	4	3	4	4	4	M
BAV (bridge to decision)	4	5	6	5	5	5	5	5	2	5	5	4	6	4	4	5	6	5	M
AVR (TAVR or SAVR)	6	8	8	6	7	7	7	5	2	7	7	7	7	7	7	7	7	7	Α

17. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo• LVEF 20 to <50%• Low flow• Low gradient• No flow reserve on low dose dobutamine echo• Minimal calcification on aortic valve on echo and/or CT• High or intermediate surgical risk	No Intervention	7	7	3	8	7	3	7	7	4	3	8	6	7	8	3	7	8	7	Α
	BAV (bridge to decision)	3	4	5	4	1	5	2	3	5	4	3	3	4	2	3	3	3	3	R
	AVR (TAVR or SAVR)	2	2	8	4	1	8	2	2	7	7	2	6	4	2	7	2	1	2	R
18. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)• LVEF <20%• Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo• High or intermediate surgical risk	No Intervention	1	1	7	5	1	7	3	3	1	7	3	1	4	3	5	3	3	3	R
	BAV (bridge to decision)	4	5	1	4	1	3	5	5	2	3	5	4	8	4	5	5	5	4	M
	AVR (TAVR or SAVR)	8	8	2	7	9	3	7	7	8	2	7	8	7	7	7	7	8	7	Α

19. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)• LVEF <20%• Mean gradient <20 mmHg on resting echo• No flow reserve on low dose dobutamine echo• High or intermediate surgical risk	No Intervention	5	9	8	8	9	8	6	6	7	7	7	4	6	6	7	6	8	7	Α
	BAV (bridge to decision)	4	4	2	5	1	3	4	4	3	3	4	4	4	4	3	4	4	4	M
	AVR (TAVR or SAVR)	6	2	3	4	1	3	3	3	2	3	3	6	3	3	2	3	1	3	R
20. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo• LVEF <20%• Low flow• Low gradient• Flow reserve on low dose dobutamine echo• Truly severe AS• High or intermediate surgical risk	No Intervention	2	2	3	7	1	3	3	3	3	3	4	3	4	3	4	3	3	3	R
	BAV (bridge to decision)	4	7	5	5	1	4	5	5	5	5	5	3	7	5	5	5	4	5	M
	AVR (TAVR or SAVR)	8	8	7	5	7	8	7	7	7	7	7	7	6	7	7	7	7	7	А

		21. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2) on resting echo• LVEF <20%• Low flow• Low gradient• Flow reserve on low dose dobutamine echo• Pseudo severe AS• High or intermediate surgical risk	No Intervention	8	7	6	8	7	5	7	9	7	7	8	7	7	7	8	7	6	7	Α
			BAV (bridge to decision)	2	3	4	3	1	5	2	1	2	4	2	3	3	2	2	2	5	2	R
			AVR (TAVR or SAVR)	1	2	3	3	1	3	2	1	2	3	1	3	3	2	2	2	5	2	R
Table 2: Flow, Gradient, and Ejection Fraction	Ejectio n Fractio	22. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)• Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo• Symptomatic• Intermediate or high surgical risk	No Intervention	1	1	3	4	1	2	1	1	1	1	1	1	1	1	1	1	1	1	R
			BAV (bridge to decision)	4	1	5	4	1	6	2	2	2	2	1	1	3	2	2	2	2	2	R
			AVR (TAVR or SAVR)	9	9	7	8	9	8	9	9	9	9	9	8	9	9	9	9	9	9	А

23. • AVA ≤1.0 cm2 (or indexed AVA ≤0.6 cm2/m2)• Vmax ≥4 m/sec or mean gradient ≥40 mmHg on resting echo• Symptomatic• Low surgical risk	No Intervention	1	1	7	3	1	7	1	1	1	1	1	1	1	1	1	1	1	1	R
	BAV (bridge to decision)	4	2	3	3	1	3	1	1	1	1	1	1	3	1	1	1	1	1	R
	AVR (TAVR or SAVR)	9	9	2	9	9	3	9	9	9	9	9	9	9	9	9	9	9	9	Α
24. • AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)• Low flow• Low gradient• Symptomatic• Evidence of a severely calcified valve• Clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms• High or intermediate surgical risk	No Intervention	2	2	1	4	1	3	2	2	2	1	2	3	1	2	2	2	1	2	R
	BAV (bridge to decision)	4	6	3	5	1	1	3	4	3	4	3	4	6	3	2	2	3	3	R
	AVR (TAVR or SAVR)	8	8	9	6	9	2	8	8	8	8	8	7	7	8	8	8	8	8	А

25. • AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)• Low flow• Low gradient• Symptomatic• Evidence of a severely calcified valve• Clinical, hemodynamic, and anatomic data support valve obstruction as the most likely cause of symptoms• Low surgical risk	No Intervention	2	1	1	3	1	1	1	1	1	1	1	2	3	1	1	1	2	1	R
	BAV (bridge to decision)	4	4	1	4	1	2	1	1	1	1	1	2	6	1	2	1	4	1	R
	AVR (TAVR or SAVR)	9	7	9	7	9	9	9	9	9	9	9	8	7	9	9	9	8	9	Α
26. • AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)• Low flow• Low gradient• Evidence of a severely calcified valve• Asymptomatic• High or intermediate surgical risk	No Intervention	6	3	3	7	9	1	6	7	6	4	6	7	3	8	7	6	7	6	М
	BAV (bridge to decision)	5	6	3	3	1	3	2	1	2	4	2	2	7	2	3	2	3	3	R

	AVR (TAVR or SAVR)	4	7	9	4	4	8	3	2	3	6	3	4	6	3	3	3	3	4	M
27. • AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)• Low flow• Low gradient• Evidence of a severely calcified valve• Asymptomatic• Low surgical risk	No Intervention	6	3	1	7	9	1	6	7	6	4	6	7	5	7	7	6	7	6	M
	BAV (bridge to decision)	5	5	1	4	1	2	2	1	2	4	2	2	3	1	3	2	3	2	R
	AVR (TAVR or SAVR)	4	6	9	4	4	9	4	3	3	4	4	4	5	3	3	4	3	4	M
28. • AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)• Normal flow• Low gradient• Confirmation of internal consistency of the AVA, flow, and gradient measurements• Evidence of a severely calcified valve• Symptoms believed to be due to AS• High or intermediate surgical risk	No Intervention	2	4	6	4	3	6	Э	Э	Э	4	4	Э	3	Э	Э	Э	3	3	R

	ı	ı																				
			BAV (bridge to decision)	4	8	3	4	1	3	4	4	4	4	4	3	7	4	4	4	5	4	M
			AVR (TAVR or SAVR)	8	6	3	8	7	3	7	7	7	4	6	7	6	7	7	7	7	7	А
		29. • AVA ≤1.0 cm2 (and indexed AVA ≤0.6 cm2/m2)• Normal flow• Low gradient• Confirmation of internal consistency of the AVA, flow, and gradient measurements• Evidence of a severely calcified valve• Symptoms believed to be due to AS• Low surgical risk	No Intervention	2	4	6	3	1	5	3	2	3	2	4	3	2	3	3	3	3	3	R
			BAV (bridge to decision)	4	7	2	3	1	2	3	1	3	4	4	2	7	3	4	3	4	3	R
			AVR (TAVR or SAVR)	8	6	5	7	7	4	7	8	7	7	6	8	6	7	7	7	9	7	Α
Table 3: Severe AS: High or Extreme Risk Patients	Multipl e Comor	30. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by comorbidities than AS• Anticipated life expectancy >1 year	No Intervention	4	2	2	5	5	4	4	4	4	5	4	3	5	4	5	4	4	4	M

	BAV (as bridge or palliative care)	5	4	3	4	5	2	5	5	3	5	4	4	4	5	5	5	5	5	M
	TAVR	7	8	8	5	5	7	7	7	4	5	7	7	6	7	7	7	8	7	Α
	SAVR	4	4	8	5	5	4	4	4	3	5	4	5	4	6	5	4	7	4	M
31. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by AS than comorbidities• Anticipated life expectancy >1 year	No Intervention	2	2	1	3	1	2	2	2	2	2	2	2	3	2	2	2	2	2	R
	BAV (as bridge or palliative care)	4	4	2	4	3	2	4	4	4	5	4	2	4	4	4	4	5	4	M
	TAVR	8	9	9	7	9	8	8	8	8	7	8	9	6	8	8	8	8	8	Α
	SAVR	5	4	9	6	9	5	5	8	5	5	5	7	6	5	5	5	7	5	M
32. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by comorbidities than AS• Anticipated life expectancy <1 year		8	5	5	7	9	8	8	9	8	8	8	7	7	8	8	8	7	8	А

	BAV (as bridge or palliative care)	5	7	8	5	4	2	5	5	3	5	5	4	6	5	5	5	6	5	M
	TAVR	3	2	6	3	1	2	3	2	3	3	3	5	3	3	3	3	4	3	R
	SAVR	1	1	2	3	1	1	1	1	1	2	1	3	1	1	1	1	3	1	R
33. • Severe symptomatic AS• STS PROM 8-15%• Health status seems to be influenced more by AS than comorbidities• Anticipated life expectancy <1 year	No Intervention	6	3	1	5	4	6	6	6	7	5	6	5	4	5	7	6	6	6	M
	BAV (as bridge or palliative care)	6	8	4	5	4	2	6	5	6	4	6	4	4	5	5	6	6	5	М
	TAVR	4	2	9	5	4	3	4	3	3	5	4	7	3	4	3	4	6	4	M
	SAVR	2	1	9	4	4	2	2	2	2	5	3	5	3	2	2	2	3	2	R
34. • Severe symptomatic AS• STS PROM >15%• Health status seems to be influenced more by comorbidities than AS• Anticipated life expectancy >1 year	No Intervention	6	6	6	7	4	4	6	7	6	5	6	6	4	5	5	6	5	6	M

		BAV (as bridge or palliative care)	5	7	5	4	2	2	5	5	5	5	5	4	4	5	5	5	5	5	M
		TAVR	6	1	6	4	4	6	6	6	5	5	6	7	7	5	5	6	8	6	M
		SAVR	2	1	2	3	4	2	2	2	3	2	3	3	4	2	2	2	5	2	R
	35. • Severe symptomatic AS• STS PROM >15%• Health status seems to be influenced more by AS than comorbidities• Anticipated life expectancy >1 year	No Intervention	4	3	4	5	4	6	4	4	6	5	4	4	3	4	5	4	5	4	M
		BAV (as bridge or palliative care)	5	7	5	5	2	2	5	5	5	5	4	4	3	5	5	5	5	5	M
		TAVR	7	8	7	5	7	7	7	7	7	5	7	8	7	7	6	7	8	7	Α
		SAVR	3	2	3	3	7	3	3	3	2	2	4	4	5	2	2	3	5	3	R
S S S S S S S S S S	36. • Severe symptomatic AS• STS PROM >15%• Health status seems to be influenced more by comorbidities than AS• Anticipated life expectancy <1 year	No Intervention	8	5	8	7	9	8	8	8	8	5	8	8	7	8	8	8	7	8	Α
		BAV (as bridge or palliative care)	4	7	4	4	3	1	4	4	4	5	4	3	5	4	5	4	5	4	M

		TAVR	3	4	2	3	3	1	3	3	3	5	3	5	3	2	3	3	2	3	R
		SAVR	1	1	1	2	3	1	1	1	1	2	1	2	1	1	1	1	1	1	R
	37. • Severe symptomatic AS STS PROM >15%• Health status seems to be influenced more by AS that comorbidities• Anticipated life expectancy <1 year		7	3	7	7	5	7	7	9	6	5	7	6	7	8	7	7	7	7	А
		BAV (as bridge or palliative care)	6	9	6	5	3	2	6	6	6	5	6	4	4	4	5	6	5	5	M
		TAVR	3	3	3	4	5	5	3	3	4	5	3	7	6	2	3	3	2	3	R
		SAVR	1	1	1	3	4	1	1	1	2	2	1	2	1	1	1	1	1	1	R
Table 3: Severe AS: High or Extreme Risk Patients	With Frailty or Disabili ty Fatigue, but no shortness of breath• Normal BNP	No Intervention	5	3	4	7	5	3	5	5	5	5	5	6	5	5	6	5	6	5	M
		BAV (as bridge or palliative care)	4	5	5	3	2	2	5	4	4	5	4	4	4	4	3	4	5	4	M
		TAVR	6	7	5	4	5	3	5	5	5	5	5	6	6	5	6	5	6	5	M
		SAVR	5	3	5	3	4	1	5	3	3	2	3	4	1	3	5	5	6	3	R

39. • Severe AS (Vmax 4-4.9 m/s Frail• No chest pain or syncope• Fatigue, but no shortness of breath• BNP elevated	No Intervention	4	3	2	6	5	3	4	4	4	5	4	5	4	4	4	4	3	4	M
	BAV (as bridge or palliative care)	4	6	4	4	2	3	4	4	4	5	4	4	4	4	3	4	5	4	M
	TAVR	7	7	6	5	7	3	7	6	7	5	7	7	6	7	7	7	8	7	Α
	SAVR	4	3	4	4	7	3	6	4	3	2	3	5	2	3	4	7	6	4	M
40. • Very severed AS (Vmax ≥5 m/s)• Frail• No chest pain or syncope• Fatigued but no shortness of breath• Normat BNP	, I No Intervention	4	3	1	5	5	3	4	4	4	5	4	4	3	4	5	4	5	4	M
	BAV (as bridge or palliative care)	4	6	4	3	2	2	5	5	5	5	5	4	4	5	3	5	5	5	M
	TAVR	7	7	8	4	5	5	7	7	7	8	7	7	6	7	7	7	8	7	Α
	SAVR	4	3	8	4	5	1	4	4	3	5	4	3	1	4	5	7	6	4	M
41. • Very severed AS (Vmax ≥5 m/s)• Frail• No chest pain or syncope• Fatigue but no shortness of breath• BNP elevated		3	2	1	5	5	3	3	3	3	5	3	3	1	3	4	3	3	3	R

	BAV (as bridge or palliative care)	5	6	4	3	2	2	5	5	5	5	5	4	4	5	5	5	5	5	M
	TAVR	6	8	9	6	7	6	8	8	7	8	8	8	6	8	7	8	8	8	Α
	SAVR	4	3	8	4	7	4	4	4	3	5	5	4	1	4	5	8	6	4	M
42. • Severe AS (Vmax ≥4 m/s)• Dependent in more than 3 activities of daily living (bathing, dressing, eating, ambulating, to lleting, transferring)• Shortness of breath	No Intervention	5	3	3	5	9	3	5	5	5	5	5	7	6	5	5	5	5	5	M
	BAV (as bridge or palliative care)	5	6	5	5	1	2	5	5	5	5	5	3	4	5	5	5	5	5	M
	TAVR	5	7	8	5	1	5	3	5	5	5	5	6	7	5	5	5	8	5	M
	SAVR	3	2	3	4	1	2	2	3	2	2	2	3	1	2	2	2	3	2	R
43. • Severe AS (Vmax ≥4 m/s)• Dependent in more than 3 activities of daily living (bathing, dressing, eating, ambulating, to lleting, transferring)• Fatigued, but not short of breath	No Intervention	6	3	4	5	9	3	6	6	6	5	6	8	6	6	5	6	5	6	M

			BAV (as bridge or palliative care)	4	6	4	4	1	2	4	4	4	5	4	2	3	4	5	4	5	4	M
			TAVR	4	7	7	4	1	5	3	3	4	2	3	5	6	3	3	3	8	4	M
			SAVR	3	2	3	3	1	2	2	2	2	2	2	2	2	2	2	2	3	2	R
Table 3: Severe AS: High or Extreme Risk Patients	Due to Anato my	44. • Severe symptomatic AS• Porcelain aorta or hostile chest• Otherwise high or intermediate surgical risk due to comorbidities		2	1	1	3	1	2	2	2	3	2	2	1	3	2	2	2	2	2	R
			BAV (as bridge or palliative care)	4	3	4	3	1	3	4	3	4	5	4	4	3	4	2	4	4	4	M
			TAVR	8	9	9	8	9	8	8	8	8	8	8	8	8	8	8	8	8	8	Α
			SAVR	3	2	3	3	5	3	3	4	3	5	3	4	1	2	3	3	3	3	R
		45. • Severe symptomatic AS• Porcelain aorta or hostile chest• Otherwise low surgical risk due to comorbidities	No Intervention	1	1	1	3	1	2	1	1	1	2	1	1	2	1	2	1	1	1	R
			BAV (as bridge or palliative care)	3	3	1	3	1	3	3	2	2	2	3	4	3	3	2	3	3	3	R
			TAVR	8	9	9	8	9	8	8	8	7	8	8	8	8	9	8	8	8	8	Α
			SAVR	4	2	3	4	6	6	4	5	6	8	4	5	4	4	5	4	6	4	M

Table 3: Severe AS: High or Extreme Risk Patients	Specifi c Comor	46. • Severe AS• Oxygen dependent lung disease• Shortness of breath• BNP normal	No Intervention	5	2	2	7	5	5	5	5	3	5	5	6	4	5	5	5	6	5	M
			BAV (as bridge or palliative care)	5	5	4	5	5	3	5	5	5	5	5	4	3	5	5	5	5	5	M
			TAVR	7	7	8	4	5	7	7	7	7	8	7	6	5	7	5	7	6	7	Α
			SAVR	3	2	7	3	5	3	3	3	6	5	3	4	1	3	2	4	5	3	R
		47. • Severe AS• Oxygen dependent lung disease• Shortness of breath• BNP elevated	No Intervention	3	1	2	6	5	3	3	3	თ	2	3	4	4	3	3	3	3	3	R
			BAV (as bridge or palliative care)	5	7	4	5	5	3	5	5	5	5	5	4	3	5	5	5	6	5	M
			TAVR	8	7	9	5	7	8	8	8	8	8	8	7	7	8	7	8	8	8	Α
			SAVR	3	1	7	4	7	6	3	4	6	5	3	4	1	3	3	5	6	4	M
		48. • Severe symptomatic AS• End-stage renal disease• Longstanding dialysis, not a renal transplant candidate• Multiple co-morbidities• STS PROM >15%	No Intervention	5	3	4	5	9	5	5	3	5	5	5	2	5	6	5	5	5	5	M

	BAV (as bridge or palliative care)	4	7	7	4	1	3	4	3	4	5	4	4	1	4	5	4	5	4	M
	TAVR	6	7	8	4	9	7	6	7	6	5	6	8	6	6	5	6	8	6	M
	SAVR	2	2	2	2	9	2	2	7	2	2	2	3	2	2	3	2	3	2	R
49. • Severe symptomatic AS• End-stage renal disease• Short time on dialysis• Renal transplant candidate• Non-diabetic, non-hypertensive etiology	No Intervention	3	1	1	5	1	3	3	3	3	2	3	3	2	3	3	3	3	3	R
	BAV (as bridge or palliative care)	3	6	4	4	1	3	3	3	3	2	3	4	2	3	3	3	4	3	R
	TAVR	7	8	8	6	9	7	7	7	7	8	7	8	7	8	7	7	8	7	Α
	SAVR	7	2	8	4	9	7	7	7	7	8	7	5	5	7	7	7	7	7	Α
50. • Severe symptomatic AS• Cirrhosis with MELD >14	No Intervention	5	2	4	5	9	4	5	5	4	5	5	3	6	5	5	5	7	5	M
	BAV (as bridge or palliative care)	5	4	4	4	1	2	5	5	4	5	5	4	3	5	5	5	5	5	M
	TAVR	7	7	6	5	1	7	7	7	7	8	7	8	6	7	7	7	6	7	Α
	SAVR	2	2	4	3	1	6	2	2	1	2	2	6	3	2	3	2	2	2	R
51. • Severe symptomatic AS• Cirrhosis with MELD <10	No Intervention	3	1	2	3	9	3	3	3	3	2	3	2	3	3	3	3	3	3	R

	BAV (as bridge or palliative care)	4	5	4	3	1	3	4	4	4	5	4	3	3	4	5	4	5	4	M
	TAVR	7	8	9	7	6	8	7	7	7	8	7	8	7	8	7	7	8	7	Α
	SAVR	5	4	4	5	6	6	6	7	4	5	6	6	4	7	5	6	5	5	M
52. • Severe symptomatic AS• Moderate to severe dementia (minimally oriented)• Symptoms described by family but not verbalized by the patient	No Intervention	8	6	4	7	9	8	8	7	8	8	8	6	8	8	7	8	7	8	Α
	BAV (as bridge or palliative care)	3	8	5	4	1	1	3	3	3	2	3	4	3	3	3	3	3	3	R
	TAVR	2	4	5	4	1	2	2	2	2	2	2	3	4	1	2	2	2	2	R
	SAVR	1	1	2	3	1	1	1	1	1	2	1	1	1	1	1	1	1	1	R
53. • Severe symptomatic AS• Malignancy• Life expectancy >1 year	No Intervention	5	1	1	5	9	4	5	5	5	5	5	2	4	5	4	5	5	5	M
	BAV (as bridge or palliative care)	4	3	4	2	1	3	4	4	4	5	4	4	4	4	5	4	5	4	M
	TAVR	7	7	9	7	6	7	7	7	7	8	8	9	6	8	7	7	8	7	Α
	SAVR	5	4	5	5	6	6	6	6	5	5	6	6	4	7	5	7	6	6	M

	54. • Severe symptomatic AS• Malignancy• Life expectancy <1 year	No Intervention	8	4	5	7	9	7	7	8	7	2	7	6	7	7	7	7	7	7	А
		BAV (as bridge or palliative care)	5	7	7	4	1	3	5	5	5	5	5	3	4	5	5	5	4	5	M
		TAVR	2	3	4	5	1	2	2	2	2	2	3	5	4	2	3	2	3	2	R
		SAVR	1	1	1	3	1	1	1	1	1	2	1	2	1	1	1	1	1	1	R
Table 4: Symptomat ic, High Gradient, Severe AS with associated Coronary Artery Disease	55. • 1 or 2 vessel CAD, no proximal LAD involvement• High or intermediate surgical risk	TAVR	6	5	7	4	9	7	7	8	7	4	7	6	5	7	7	7	3	7	А
		TAVR + PCI	7	6	7	7	9	8	7	8	7	8	8	7	6	7	7	7	8	7	Α
		SAVR	6	5	4	4	9	8	4	3	4	2	4	2	3	4	6	4	3	4	M
		SAVR + PCI	7	4	4	3	1	2	4	4	4	2	7	1	3	4	6	4	5	4	M
		SAVR + CABG	3	7	7	6	9	8	7	8	7	8	7	2	6	7	7	7	9	7	А
	56. • 1 or 2 vessel CAD, no proximal LAD involvement• Low surgical risk	TAVR	4	4	4	3	1	7	3	1	3	6	3	7	5	2	3	3	1	3	R
		TAVR + PCI	5	5	4	4	1	7	3	1	3	6	3	7	6	2	3	3	1	3	R
		SAVR	6	5	8	3	9	7	6	3	6	5	6	2	3	6	3	6	3	6	M

	SAVR + PCI	8	5	6	4	1	7	5	3	5	4	7	5	3	5	6	5	5	5	M
	SAVR + CABG	4	8	2	7	9	7	9	9	9	8	9	8	6	9	8	9	9	8	Α
57. • 1 or 2 vessel CAD, including proximal LAD• High or intermediate surgical risk	TAVR	3	4	6	3	1	4	4	6	4	5	4	2	1	4	5	4	1	4	M
	TAVR + PCI	7	5	8	4	7	7	8	8	5	5	8	8	5	8	7	8	8	7	Α
	SAVR	3	5	2	3	1	6	3	3	3	2	3	2	1	3	3	3	1	3	R
	SAVR + PCI	7	7	4	4	1	7	3	4	3	5	6	4	1	3	6	3	3	4	M
	SAVR + CABG	9	7	7	6	9	8	7	8	7	9	7	5	7	7	7	7	9	7	А
58. • 1 or 2 vessel CAD, including proximal LAD• Low surgical risk	TAVR	3	4	3	2	1	4	2	1	2	2	2	1	1	2	3	2	1	2	R
	TAVR + PCI	4	6	3	3	1	7	3	1	3	2	3	5	5	2	3	3	2	3	R
	SAVR	3	3	6	3	1	3	3	1	3	2	3	1	1	3	3	3	1	3	R
	SAVR + PCI	7	3	6	4	1	7	3	2	3	4	6	5	1	3	6	3	3	3	R
	SAVR + CABG	8	8	9	8	9	7	9	9	9	9	9	9	7	9	8	9	9	9	А
59. • 3 vessel disease; SYNTAX < 22• High or intermediate surgical risk	TAVR	6	4	4	3	1	1	4	6	4	2	4	5	2	4	7	4	1	4	M
	TAVR + PCI	7	4	6	4	7	6	7	8	7	5	7	8	4	7	7	7	8	7	Α

	SAVR	3	2	4	3	1	3	3	3	3	2	3	1	1	3	6	3	1	3	R
	SAVR + PCI	7	4	4	4	1	6	3	6	3	2	4	5	1	3	6	3	3	4	M
	SAVR + CABG	9	8	8	7	9	7	7	7	7	8	7	6	7	7	7	7	9	7	А
60. • 3 vessel disease; SYNTAX < 22• Low surgical risk	TAVR	3	3	2	2	1	1	2	1	2	2	2	2	1	2	3	2	1	2	R
	TAVR + PCI	5	4	2	2	1	6	3	2	3	2	3	5	4	2	3	3	1	3	R
	SAVR	3	3	2	2	1	3	2	1	2	2	2	3	1	2	3	2	1	2	R
	SAVR + PCI	7	4	5	2	1	6	4	4	4	2	5	4	2	3	6	4	1	4	M
	SAVR + CABG	9	8	9	8	9	9	9	9	9	8	9	9	7	9	8	9	9	9	Α
61. • 3 vessel disease; SYNTAX ≥ 22• High or intermediate surgical risk	TAVR	6	2	4	2	1	1	4	5	3	3	4	3	3	3	5	4	1	3	R
	TAVR + PCI	8	2	4	4	7	6	6	7	6	6	6	8	5	6	5	6	8	6	M
	SAVR	3	3	6	3	1	3	2	3	3	3	3	3	1	2	3	3	1	3	R
	SAVR + PCI	6	4	4	4	1	6	4	4	4	3	4	4	2	2	6	4	3	4	M
	SAVR + CABG	7	9	8	6	9	7	7	8	5	8	8	7	6	7	7	8	9	7	Α
62. • 3 vessel disease; SYNTAX ≥ 22• Low surgical risk	TAVR	3	1	1	2	1	1	1	1	1	2	1	2	1	1	3	1	1	1	R
	TAVR + PCI	3	2	2	2	1	6	2	2	2	2	2	4	3	2	3	2	1	2	R
	SAVR	3	2	3	3	1	3	2	1	3	2	2	2	1	1	3	3	1	2	R

	Ī																				
		SAVR + PCI	8	4	2	3	1	6	3	2	3	2	4	5	2	2	5	3	1	3	R
		SAVR + CABG	9	9	9	8	9	9	9	9	9	8	9	9	7	9	8	9	9	9	Α
SY Hiç inte	s. • Left main; /NTAX < 33• gh or ermediate rgical risk	TAVR	3	3	2	3	1	2	2	3	2	2	3	1	1	2	5	2	1	2	R
		TAVR + PCI	6	5	6	4	7	6	7	7	7	5	7	7	3	4	7	7	8	7	Α
		SAVR	3	3	3	3	1	2	2	2	2	2	2	1	1	2	3	2	1	2	R
		SAVR + PCI	5	3	4	4	1	6	3	3	3	2	4	6	1	3	3	3	3	3	R
		SAVR + CABG	7	9	8	6	9	7	8	8	8	8	8	7	7	8	7	8	9	8	Α
SY	• Left main; /NTAX < 33• w surgical risk	TAVR	3	1	1	2	1	2	1	1	1	2	1	1	1	1	3	2	1	1	R
		TAVR + PCI	4	3	2	3	1	5	2	2	2	2	2	5	3	2	3	2	1	2	R
		SAVR	3	3	2	2	1	3	1	1	2	2	2	1	1	1	3	2	1	2	R
		SAVR + PCI	5	3	3	4	1	3	3	3	3	2	3	6	1	2	3	3	3	3	R
		SAVR + CABG	9	9	9	8	9	8	9	9	9	9	9	9	7	9	8	9	9	9	Α
SY Hig inte	i. • Left main; /NTAX ≥ 33• gh or ermediate rgical risk	TAVR	3	1	3	2	1	1	3	3	3	2	3	1	1	1	5	3	1	2	R
		TAVR + PCI	5	4	6	4	7	3	6	5	6	6	6	7	2	2	5	6	8	6	M
		SAVR	3	2	2	3	1	3	1	2	2	2	2	1	1	1	3	2	1	2	R
		SAVR + PCI	5	3	4	4	1	1	3	3	4	2	4	6	1	3	3	4	3	3	R

	SAVR + CABG	9	9	8	6	9	8	7	8	8	8	7	8	7	8	7	7	9	8	Α
66. • Left mail SYNTAX ≥ 33 Low surgical	•	3	1	2	2	1	1	1	1	1	2	1	1	1	1	3	1	1	1	R
	TAVR + PCI	6	3	2	3	1	1	2	1	2	2	2	3	2	2	3	2	1	2	R
	SAVR	3	2	2	3	1	1	1	1	1	2	1	1	1	1	3	1	1	1	R
	SAVR + PCI	6	3	2	4	1	1	1	1	2	2	3	3	1	1	3	2	1	2	R
	SAVR + CABG	9	9	9	8	9	9	9	9	9	9	9	9	7	9	8	9	9	9	Α
Sympt omatic symptomatic AS and Mitral Valve Diseas e	y	6	8	5	3	3	1	4	5	4	4	4	4	6	4	3	4	2	4	M
	TAVR alone	5	4	8	4	9	1	4	4	5	4	5	6	4	4	5	4	5	4	M
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-			
	TAVR + MitraClip	6	9	6	5	9	8	6	6	6	6	6	8	7	6	5	6	8	6	M
	SAVR alone	4	2	5	3	1	3	3	3	3	3	3	1	1	3	2	3	2	3	R
	SAVR + other valve or ascending aortic surgery or myectomy	7	8	8	6	9	7	7	7	7	8	7	5	7	7	7	7	9	7	А

68. • Severe symptomatic AS• Severe primary MR• Intermediate surgical risk	BAV as bridge to decision	4	6	5	3	1	1	1	3	2	1	2	3	6	1	3	2	1	2	R
	TAVR alone	4	3	6	4	9	1	2	4	3	2	3	4	4	1	3	3	2	3	R
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	5	7	5	5	3	8	3	3	3	3	3	8	6	3	3	3	4	3	R
	SAVR alone	3	1	4	3	1	3	3	3	3	3	3	1	1	3	2	3	1	3	R
	SAVR + other valve or ascending aortic surgery or myectomy	7	9	8	7	9	9	8	8	8	8	8	7	7	9	8	8	9	8	А
69. • Severe symptomatic AS• Severe primary MR• Low surgical risk	BAV as	3	2	1	2	1	1	1	1	1	1	1	2	3	1	2	1	1	1	R
	TAVR alone	3	2	1	2	1	1	1	1	1	1	1	2	3	1	2	1	1	1	R
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	3	4	3	3	1	8	2	1	2	1	2	4	6	1	3	2	1	2	R
	SAVR alone	2	1	4	3	1	3	2	1	2	1	2	1	1	1	2	2	1	2	R

	SAVR + other valve or ascending aortic surgery or myectomy	9	9	8	8	9	8	9	9	9	8	9	9	9	9	9	9	9	9	А
70. • Severe symptomatic Severe second MR• High surisk	c AS• ondary BAV as	4	7	5	4	3	1	4	5	4	5	4	5	6	4	5	4	5	4	M
	TAVR alone	6	4	8	5	9	3	5	5	5	5	5	6	3	5	7	5	5	5	M
	TAVR + PBMV	-		-	-			-	1	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	4	8	6	5	1	7	5	5	5	5	5	7	7	5	5	5	5	5	M
	SAVR alone	7	4	7	5	9	5	4	3	4	4	4	3	1	4	6	4	3	4	M
	SAVR + other valve or ascending aortic surgery or myectomy	7	8	4	6	9	7	6	7	6	8	7	4	6	6	7	6	9	7	А
71. • Severe symptomatic Severe second MR• Interme surgical risk	c AS• ondary BAV as ediate bridge to	4	6	2	3	1	1	3	3	3	1	3	4	3	3	3	3	5	3	R
	TAVR alone	6	3	7	5	9	3	4	4	4	4	4	6	3	4	3	4	3	4	M
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		

	TAVR + MitraClip	4	7	6	5	1	4	3	4	3	4	3	7	6	3	3	3	2	4	M
	SAVR alone	6	2	7	5	9	3	3	2	3	4	3	5	1	3	4	3	1	3	R
	SAVR + other valve or ascending aortic surgery or myectomy	7	9	8	6	9	8	8	8	8	8	8	7	8	8	8	8	9	8	A
	BAV as bridge to decision	4	2	1	2	1	1	1	1	1	1	1	3	2	1	2	1	2	1	R
	TAVR alone	4	1	1	3	1	3	1	1	1	1	1	4	2	1	2	1	1	1	R
	TAVR + PBMV	-		-	-			-	-	-	-	1	1	-	-	-	1	-		
	TAVR + MitraClip	3	5	1	3	1	4	2	1	2	1	2	5	3	1	2	2	1	2	R
	SAVR alone	4	1	7	4	9	3	3	1	3	1	2	5	1	3	4	3	1	3	R
	SAVR + other valve or ascending aortic surgery or myectomy	9	9	9	7	9	8	9	9	9	9	9	7	6	8	9	9	9	9	А

BAV as bridge to decision	4	8	5	2	3	1	4	4	4	3	2	2	1	4	3	4	5	4	M
TAVR alone	4	1	6	3	9	5	4	4	4	5	3	2	3	4	5	4	4	4	M
TAVR + PBMV	7	6	8	7	9	8	7	7	6	5	7	8	6	7	7	7	7	7	А
TAVR + MitraClip	-		ı	-			1	-		1	1	1	1	-	1	1			
SAVR alone	4	1	4	3	1	4	2	3	3	5	2	1	1	2	3	3	1	3	R
SAVR + other valve or ascending aortic surgery or myectomy	7	O	7	6	9	8	7	6	7	7	7	4	7	7	7	7	8	7	А
BAV as bridge to decision	4	2	5	3	5	3	4	4	4	5	4	4	2	4	5	4	5	4	M
TAVR alone	7	4	4	4	9	5	5	5	5	5	6	1	4	5	5	5	2	5	M

			TAVR + PBMV	3	4	7	1	1	1	2	1	2	1	2	4	1	2	1	2	5	2	R
			TAVR + MitraClip	-		1	-			-	-		-	-	-	1	-	-	-			
			SAVR alone	7	2	3	4	1	3	3	3	3	4	3	1	3	3	5	3	1	3	R
			SAVR + other valve or ascending aortic surgery or myectomy	5	7	7	7	9	7	7	7	7	8	7	6	7	7	7	7	8	7	А
Symptomat ic AS and Other Valve or Ascending	omatic AS and Tricusp id Valve Diseas	75. • Severe symptomatic AS• Severe secondary TR• Dilated right ventricle and/or tricuspid valve annulus ≥ 40mm• Minimal to no right ventricular dysfunction• Minimal pulmonary hypertension• Intermediate surgical risk		1	5	3	2	5	1	3	1	2	2	2	2	3	2	3	2	5	2	R
			TAVR alone	7	3	7	6	7	6	5	4	5	2	5	6	6	5	3	5	3	5	M
			TAVR + PBMV	-		-	-			-	-	-	-	-	-	1	-	-	-	-		
			TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
			SAVR alone	6	5	7	3	7	6	3	3	3	3	3	3	4	3	3	3	1	3	R

	SAVR + other valve or ascending aortic surgery or myectomy	6	9	6	7	7	8	8	8	8	8	8	8	8	8	8	8	9	8	А
Severe TR• Di ventric tricusp	omatic AS• e secondary lated right le and/or id valve s ≥ 40mm• ate to right ular ction• al nary ension• BAV as ediate bridge to	1	5	3	2	5	1	2	1	2	2	2	2	3	2	3	2	5	2	R
	TAVR alone	7	4	7	5	7	6	5	4	5	5	5	4	5	5	3	5	6	5	M
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	SAVR alone	3	4	7	3	7	7	3	4	3	3	3	2	2	3	3	3	1	3	R
	SAVR + other valve or ascending aortic surgery or myectomy	6	7	7	8	7	9	7	7	7	8	7	8	7	7	7	7	9	7	А

77. • Severe symptomatic AS• Severe secondary TR• Dilated right ventricle and/or tricuspid valve annulus ≥ 40mm• Moderate to severe right ventricular dysfunction• Severe pulmonary hypertension• High surgical risk	BAV as bridge to	4	4	4	4	5	1	4	5	4	5	4	2	5	4	5	4	5	4	M
	TAVR alone	8	7	7	7	7	6	7	7	7	6	7	6	6	7	7	7	7	7	Α
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	SAVR alone	4	3	2	5	7	7	2	3	2	3	2	2	1	2	3	2	1	2	R
	SAVR + other valve or ascending aortic surgery or myectomy	6	3	3	6	7	8	5	5	5	5	5	6	6	5	7	5	9	5	M

Table 5: Severe Symptomat ic AS and Other Valve or Ascending Aortic Pathology	omatic AS, Bicuspi d Aortic	78. • Severe symptomatic AS• Bicuspid aortic valve• High surgical risk• Ascending aorta < 4.5cm	BAV as bridge to decision	3	3	4	2	1	1	2	2	2	2	1	2	1	2	3	2	5	2	R
			TAVR alone	4	8	9	4	1	8	5	6	5	5	5	6	5	5	5	5	5	5	M
			TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
			TAVR + MitraClip	-		ı	-			1	ı	ı	1	1	ı	ı	1	ı	ı	-		
			SAVR alone	7	7	9	6	7	7	5	7	7	5	7	6	7	6	5	6	7	7	Α
			SAVR + other valve or ascending aortic surgery or myectomy	3	2	1	5	7	7	6	3	3	7	6	2	3	5	7	6	9	5	M
		79. • Severe symptomatic AS• Bicuspid aortic valve• High surgical risk• Ascending aorta ≥ 4.5cm	BAV as bridge to decision	4	3	4	2	1	1	1	2	2	2	1	2	1	2	3	2	5	2	R
			TAVR alone	3	4	6	3	1	1	4	4	3	5	4	4	3	4	5	4	4	4	M
			TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
			TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		

	SAVR alone	3	2	1	5	4	3	3	4	3	3	3	2	3	3	3	3	5	3	R
	SAVR + other valve or ascending aortic surgery or myectomy	8	7	9	6	7	9	7	8	7	8	8	7	8	8	7	8	9	8	A
80. • Severe symptomatic AS• Bicuspid aortic valve• Intermediate surgical risk• Ascending aorta < 4.5cm	BAV as bridge to decision	3	2	3	2	1	1	2	1	2	1	1	2	1	1	3	1	1	1	R
	TAVR alone	7	2	7	3	1	7	4	2	4	3	3	6	5	3	3	3	2	3	R
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	SAVR alone	7	9	9	7	7	8	7	8	8	6	6	9	7	7	5	5	8	7	Α
	SAVR + other valve or ascending aortic surgery or myectomy	3	5	2	5	7	7	5	2	3	8	7	3	3	5	7	6	9	5	M

81. • Severe symptomatic AS• Bicuspid aortic valve• Intermediate surgical risk• Ascending aorta ≥ 4.5cm	BAV as bridge to decision	3	1	3	2	1	1	2	1	2	1	1	2	1	1	3	1	1	1	R
	TAVR alone	3	1	1	3	1	4	3	2	3	1	1	3	2	3	3	1	2	2	R
	TAVR + PBMV	-		-	1			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	SAVR alone	3	2	1	4	7	1	4	3	3	6	2	1	3	6	3	2	3	3	R
	SAVR + other valve or ascending aortic surgery or myectomy	8	9	9	7	7	9	7	8	8	8	9	9	8	9	8	9	9	8	A
82. • Severe symptomatic AS• Bicuspid aortic valve• Low surgical risk• Ascending aorta < 4.5cm	BAV as bridge to decision	2	1	1	1	1	1	1	1	2	1	1	1	1	1	2	1	1	1	R
	TAVR alone	4	1	3	2	1	7	1	1	2	1	1	6	3	1	2	1	2	2	R
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	SAVR alone	9	9	9	7	4	8	7	8	9	5	7	9	8	8	5	7	8	8	А

	SAVR + other valve or ascending aortic surgery or myectomy	3	5	3	5	7	6	5	2	3	8	6	2	2	6	8	6	9	5	M
83. • Severe symptomatic AS• Bicuspid aortic valve• Low surgical risk• Ascending aorta ≥ 4.5 cm	BAV as bridge to decision	1	1	1	1	1	1	1	1	2	1	1	1	1	1	2	1	1	1	R
	TAVR alone	2	1	1	2	1	1	2	1	2	1	1	4	3	1	2	1	2	1	R
	TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
	SAVR alone	3	1	1	6	7	1	5	1	2	3	1	2	2	1	3	1	3	2	R
	SAVR + other valve or ascending aortic surgery or myectomy	8	9	9	7	7	9	8	9	9	8	9	9	8	9	9	9	9	9	A

Severe Symptomat ic AS and Other Valve or Ascending Aortic	omatic AS and Basal Septal Hypertr ophy, Flow Acceler	84. • Symptomatic severe AS• Prominent basal septal hypertrophy with flow acceleration and narrowing in the LVOT• High or intermediate surgical risk		4	5	5	1	3	1	3	4	3	3	3	5	4	3	3	3	5	3	R
			TAVR alone	6	5	8	4	7	6	6	7	4	6	6	5	5	6	5	6	7	6	M
			TAVR + PBMV	-		-	-			-	-	-	-	-	-	-	-	-	1	-		
			TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
			SAVR alone	4	5	6	5	3	7	4	6	4	4	4	5	2	4	3	4	8	4	M
			SAVR + other valve or ascending aortic surger y or myectomy	5	9	8	6	7	9	7	7	7	8	7	7	7	7	7	7	8	7	A
		85. • Symptomatic severe AS• Prominent basal septal hypertrophy with flow acceleration and narrowing in the LVOT• Low surgical risk	BAV as bridge todecision	3	1	1	2	1	1	1	1	1	1	1	2	2	1	2	1	4	1	R

		TAVR alone	4	1	1	3	1	4	3	3	3	3	3	3	1	1	3	3	3	3	R
		TAVR + PBMV	-		-	-			-	1	-	-	-	-	-	-	-	-	-		
		TAVR + MitraClip	-		-	-			-	-	-	-	-	-	-	-	-	-	-		
		SAVR alone	7	1	4	4	3	7	4	6	3	4	4	6	2	4	3	4	8	4	M
		SAVR + other valve or ascending aortic surger y or myectomy	5	9	8	7	7	9	8	8	8	8	8	8	8	9	8	8	8	8	А
Table 6: Non- Cardiac Surgery	86. • Symptomatic severe/critical AS• Elective major surgery• Non obstructive CAD	No Intervention	2	1	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	R
		BAV	5	4	4	2	1	4	4	1	4	1	4	3	1	3	3	4	5	4	M
		AVR (TAVR or SAVR)	7	8	8	8	9	8	8	9	8	8	7	9	8	8	8	8	9	8	А
	87. • Symptomatic severe/critical AS• Urgent major surgery• Non obstructive CAD	No Intervention	6	1	3	3	9	1	2	2	2	2	3	4	1	2	5	2	1	2	R
		BAV	8	7	6	4	1	7	6	6	6	5	6	4	6	6	5	6	5	6	M
		AVR (TAVR or SAVR)	1	2	7	4	1	5	7	7	7	8	7	7	6	7	7	7	8	7	Α

88. • Asymptomatic severe/critical AS• Elective major surgery• Non obstructive CAD• No signs of cardiac decompensation	No Intervention	3	3	4	7	9	4	4	2	4	2	5	7	1	4	3	5	5	4	M
	BAV	6	5	3	2	1	4	3	1	3	2	2	2	4	3	3	3	5	3	R
	AVR (TAVR or SAVR)	5	7	7	3	9	6	7	7	7	8	7	4	7	7	7	6	9	7	А
89. • Asymptomatic severe/critical AS• Urgent major surgery• Non obstructive CAD• No signs of cardiac decompensation	No Intervention	5	1	5	7	9	2	5	3	5	2	5	8	3	5	5	5	5	5	M
	BAV	4	8	4	3	1	5	4	5	4	5	4	4	6	4	5	4	5	4	M
	AVR (TAVR or SAVR)	1	2	5	3	1	4	5	7	5	8	5	4	6	5	7	5	7	5	M
Table 7: Failing Aortic Valve Bioprosthe sis 90. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size ≥23mm• High surgical risk	BAV	4	1	1	1	1	1	1	1	1	2	1	1	1	1	2	1	1	1	R
	TAVR	8	9	9	8	9	9	8	8	8	7	8	8	7	8	8	8	8	8	Α
	SAVR	7	5	7	5	9	7	7	6	7	7	6	6	6	7	7	6	9	7	Α

91. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size ≥23mm• Intermediate surgical risk	BAV	3	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	R
	TAVR	8	8	7	7	1	8	7	7	7	5	8	8	4	6	8	7	8	7	Α
	SAVR	8	6	8	7	9	7	8	8	8	8	7	7	8	8	7	8	9	8	Α
92. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis — size 21 mm• High surgical risk	BAV	4	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	R
	TAVR	6	5	7	4	9	7	6	6	6	5	6	6	4	6	7	6	8	6	M
	SAVR	5	5	7	6	9	7	7	7	7	7	7	7	7	7	7	7	9	7	Α
93. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size 21 mm• Intermediate surgical risk	BAV	4	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	R
	TAVR	6	5	5	4	1	7	5	5	6	3	6	7	3	5	7	6	8	5	M
	SAVR	7	7	8	7	9	8	7	7	8	8	8	6	8	8	7	8	9	8	Α

94. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis — size ≤19 mm• High surgical risk	BAV	1	1	2	1	1	1	1	1	1	1	1	1	3	1	1	1	1	1	R
	TAVR	4	4	7	5	4	4	4	5	5	4	4	6	6	5	5	4	6	5	M
	SAVR	7	7	7	7	7	7	8	7	7	8	7	7	6	7	7	7	7	7	Α
95. • Severe symptomatic AS or AR• Degenerative surgical bioprosthesis – size ≤19 mm• Intermediate surgical risk	BAV	4	1	1	1	1	1	1	1	1	1	1	1	1	1	2	1	1	1	R
	TAVR	3	2	4	2	1	6	3	3	3	3	2	2	1	2	6	3	5	3	R
	SAVR	8	8	8	8	9	8	8	8	8	8	8	8	7	8	7	8	7	8	Α